| Views | |
|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 215 |
| July 2024 | August 2024 | September 2024 | October 2024 | November 2024 | December 2024 | January 2025 | |
|---|---|---|---|---|---|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 1 | 4 | 3 | 5 | 1 | 2 | 3 |
| Views | |
|---|---|
| s12967-015-0456-6.pdf | 168 |
